title: Botulinum toxin type a versus topical 20% aluminum chloride for the treatment of moderate to severe primary focal axillary hyperhidrosis.
abstract: Severe hyperhidrosis affects 2.8% of the population and can be emotionally devastating. First-line therapy employs topical agents such as aluminum chloride (AC), but efficacy and tolerability vary widely. Botulinum toxin type A (BTX-A) is FDA-approved for the treatment of primary focal axillary hyperhidrosis unresponsive to topical therapy. A single-center, randomized, parallel, open-label, 12-week study was performed to compare the efficacy and safety of BTX-A with 20% AC for the treatment of primary focal axillary hyperhidrosis. Twenty-five subjects were randomized to either BTX-A or AC treatment, and were evaluated for treatment response by an improvement of > or =2 grades on the Hyperhidrosis Disease Severity Scale (HDSS). At week 4, 92% of the subjects in the BTX-A group achieved treatment response compared with 33% of the subjects in the AC group. Overall, treatment with BTX-A was more effective and provided greater patient satisfaction than with AC. Treatment with AC was effective and tolerated in 29% of the subjects.
authors: Department of Dermatology, Saint Louis University School of Medicine, St. Louis, MO, USA.
authors: Katherine H
authors: KH
authors: Flanagan
authors: Rosemary
authors: R
authors: King
authors: Dee Anna
authors: DA
authors: Glaser
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000077410:Aluminum Chloride; D017607:Aluminum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D001252:Astringents / Q000009:adverse effects / Q000627:therapeutic use*; D001365:Axilla / Q000473:pathology; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000627:therapeutic use*; D002712:Chlorides / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006945:Hyperhidrosis / Q000188:drug therapy*; D007267:Injections; D008297:Male; D009498:Neurotoxins / Q000009:adverse effects / Q000627:therapeutic use*; D017060:Patient Satisfaction; D012720:Severity of Illness Index; D018434:Sickness Impact Profile; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D017607:Aluminum Compounds; D001252:Astringents; D002712:Chlorides; D009498:Neurotoxins; D000077410:Aluminum Chloride; D019274:Botulinum Toxins, Type A